Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota
With improved standards of living, the incidence of multiple metabolic disorders has increased year by year, especially major risk factors for cardiovascular disease such as hyperglycemia and hyperlipidemia, continues to increase. Emerging epidemiological data and clinical trials have shown the addi...
Main Authors: | Qi-You Ding, Jia-Xing Tian, Min Li, Feng-Mei Lian, Lin-Hua Zhao, Xiu-Xiu Wei, Lin Han, Yu-Jiao Zheng, Ze-Zheng Gao, Hao-Yu Yang, Xin-Yi Fang, Xiao-lin Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2020.530160/full |
Similar Items
-
Gut Microbiota and Metabolic Disorders
by: Kyu Yeon Hur, et al.
Published: (2015-06-01) -
Metformin effect on gut microbiota: insights for HIV-related inflammation
by: Jing Ouyang, et al.
Published: (2020-03-01) -
The Cross-talk Relationship between Metformin and Gut Microbiota
by: Hyder O. Mirghani. MD, et al.
Published: (2020-12-01) -
The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia
by: Xiu Liu, et al.
Published: (2020-03-01) -
Depletion of Gut Microbiota Impairs Gut Barrier Function and Antiviral Immune Defense in the Liver
by: Weina Guo, et al.
Published: (2021-03-01)